Abstract
The behavior of oxypurines has been evaluated in 20 normal subjects and in 20 patients affected by lymphoproliferative diseases (LPD). Plasma and 24 h urine were analyzed for uric acid, hypoxanthine and xanthine levels by high performance liquid chromatography (HPLC), according to a previously described procedure (1). 6 patients had myeloma, 5 lymphoma, 9 acute lymphocytic leukemia. Determinations were carried out before and after pharmacological treatment. There was an evident rise in oxypurines in the plasma and urine of all patients with representative patterns for each disease. Oxypurines were substantially reduced - although only slightly - after chemotherapy, and their behavior was not related to that of uric acid. The changes observed may be due either to an accelerated synthesis of purine nucleotides, to an enhanced degradation, or to release from the cells. These aspects are currently under investigation, as well the possibility of using this determination as marker for the disease.
(1) L.Lorenzi et al., Tumori 73, 289–294, 1987.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marinello, E., Vannoni, D., Porcelli, B. et al. 31 EVALUATION OF OXYPURINES BY HPLC IN LYMPHOPROLIFERATIVE DISEASES. Pediatr Res 24, 116 (1988). https://doi.org/10.1203/00006450-198807000-00055
Issue Date:
DOI: https://doi.org/10.1203/00006450-198807000-00055